ASCO24 Updates – Jordi Ramon on EGFR-Mutant Lung Cancer: Targeted Therapy and Resistance Strategies

The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most prestigious conferences in the field of oncology. This year, the meeting took place from May 31 to June 4 in Chicago, Illinois. The event gathers oncologists, researchers, and healthcare professionals from around the world to discuss the latest advancements in cancer research, treatment, and patient care. Keynote sessions, research presentations, and panel discussions are typically part of the agenda, providing attendees with valuable insights into emerging trends and innovations in oncology.

This year, OncoDaily was at ASCO 2024 for the first time covering the meeting on-site. We had the pleasure of interviewing researchers who summarized the highlights of their work.

In this video, Jordi Ramon from Gustave-Roussy, shares insights from ‘Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non–Small-Cell Lung Cancer’

I’m Jordi Ramon, medical oncologist in Gustave-Roussy in France, and we’ll talk about an educational session about the management for patients with EGFR mutant non-small cell lung cancer, regardless the stage of the disease. This genomic alteration corresponds approximately to 15 percent of all patients with non-small cell lung cancer, and it’s higher in patients with Asian ethnicity.

It’s really important that today the third generation EGFR TKI is the standard of care, but probably in the coming future, the combination approaches either of this third generation TKI with chemotherapy or Amivantamab will be the standard of care.

It’s really important also to try to address how to manage the potential sequential treatment approaches for those tumors that become resistant either to the monotherapy or the combination, and in this scenario, I think that will be really important in the future, the role of the antibody drug conjugated, these clever chemotherapies, specific antibodies that target the specific conditions expressed in the cancer cell surface, and in these antibodies are linked the payloads or the chemotherapies.

I think that is a very evolving or rapid evolving treatment landscape for this genomic alteration, but new opportunities are reported not only in the first line, also for those patients that have a recurrence either with a monotherapy or also with a combination. Also, it’s really important that all of these treatment strategies are relevant in oncogenic tumors, not only in the metastatic disease.

Also, we know that these targeted therapies specifically for EGFR mutant tumors are the newest standard of care in the adjuvant setting, and also during this Congress will be presented the results of LOWER trial for those patients with a stage three and resectable non small cell cancer with EGFR mutation that after chemoradiotherapy, osimertinib as a consolidation treatment really improved the outcome compared with the placebo. So today, the targeted therapies for patients with EGFR mutant tumors is the standard of care regardless the stage of the disease.

More videos and content from ASCO 2024 on OncoDaily.